Arikace: Completed Phase III enrollment

Insmed completed enrollment of over 300 patients in the open-label, international Phase III CLEAR-108 trial comparing once-daily 560 mg Arikace administered with the eFlow Nebulizer System from Pari GmbH (Starnberg, Germany) vs. twice-daily 300 mg TOBI Podhaler for the first 28 days of a 56-day cycle for 3 cycles. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets TOBI Podhaler to deliver tobramycin inhalation powder. ...